3v1g: Difference between revisions
No edit summary |
No edit summary |
||
Line 1: | Line 1: | ||
==Forestalling insulin fibrillation by insertion of a chiral clamp mechanism-based application of protein engineering to global health== | ==Forestalling insulin fibrillation by insertion of a chiral clamp mechanism-based application of protein engineering to global health== | ||
<StructureSection load='3v1g' size='340' side='right' caption='[[3v1g]], [[Resolution|resolution]] 2.20Å' scene=''> | <StructureSection load='3v1g' size='340' side='right' caption='[[3v1g]], [[Resolution|resolution]] 2.20Å' scene=''> | ||
Line 6: | Line 7: | ||
<tr id='NonStdRes'><td class="sblockLbl"><b>[[Non-Standard_Residue|NonStd Res:]]</b></td><td class="sblockDat"><scene name='pdbligand=DGL:D-GLUTAMIC+ACID'>DGL</scene></td></tr> | <tr id='NonStdRes'><td class="sblockLbl"><b>[[Non-Standard_Residue|NonStd Res:]]</b></td><td class="sblockDat"><scene name='pdbligand=DGL:D-GLUTAMIC+ACID'>DGL</scene></td></tr> | ||
<tr id='related'><td class="sblockLbl"><b>[[Related_structure|Related:]]</b></td><td class="sblockDat">[[1trz|1trz]], [[3v19|3v19]]</td></tr> | <tr id='related'><td class="sblockLbl"><b>[[Related_structure|Related:]]</b></td><td class="sblockDat">[[1trz|1trz]], [[3v19|3v19]]</td></tr> | ||
<tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=3v1g FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=3v1g OCA], [http://www.rcsb.org/pdb/explore.do?structureId=3v1g RCSB], [http://www.ebi.ac.uk/pdbsum/3v1g PDBsum]</span></td></tr> | <tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=3v1g FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=3v1g OCA], [http://pdbe.org/3v1g PDBe], [http://www.rcsb.org/pdb/explore.do?structureId=3v1g RCSB], [http://www.ebi.ac.uk/pdbsum/3v1g PDBsum], [http://prosat.h-its.org/prosat/prosatexe?pdbcode=3v1g ProSAT]</span></td></tr> | ||
</table> | </table> | ||
== Disease == | == Disease == |
Revision as of 20:10, 4 August 2016
Forestalling insulin fibrillation by insertion of a chiral clamp mechanism-based application of protein engineering to global healthForestalling insulin fibrillation by insertion of a chiral clamp mechanism-based application of protein engineering to global health
Structural highlights
Disease[INS_HUMAN] Defects in INS are the cause of familial hyperproinsulinemia (FHPRI) [MIM:176730].[1] [2] [3] [4] Defects in INS are a cause of diabetes mellitus insulin-dependent type 2 (IDDM2) [MIM:125852]. IDDM2 is a multifactorial disorder of glucose homeostasis that is characterized by susceptibility to ketoacidosis in the absence of insulin therapy. Clinical fetaures are polydipsia, polyphagia and polyuria which result from hyperglycemia-induced osmotic diuresis and secondary thirst. These derangements result in long-term complications that affect the eyes, kidneys, nerves, and blood vessels.[5] Defects in INS are a cause of diabetes mellitus permanent neonatal (PNDM) [MIM:606176]. PNDM is a rare form of diabetes distinct from childhood-onset autoimmune diabetes mellitus type 1. It is characterized by insulin-requiring hyperglycemia that is diagnosed within the first months of life. Permanent neonatal diabetes requires lifelong therapy.[6] [7] Defects in INS are a cause of maturity-onset diabetes of the young type 10 (MODY10) [MIM:613370]. MODY10 is a form of diabetes that is characterized by an autosomal dominant mode of inheritance, onset in childhood or early adulthood (usually before 25 years of age), a primary defect in insulin secretion and frequent insulin-independence at the beginning of the disease.[8] [9] [10] Function[INS_HUMAN] Insulin decreases blood glucose concentration. It increases cell permeability to monosaccharides, amino acids and fatty acids. It accelerates glycolysis, the pentose phosphate cycle, and glycogen synthesis in liver. See AlsoReferences
|
|